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From a clinical perspective, angiogenesis is an
important component of acute and chronic psoriatic
skin lesions as they are erythematous and display a
tendency to bleed after super®cial removal of scale.
By routine histology, numerous microscopic vascular
abnormalities are also present. The structural expan-
sion of capillaries and distinctive activated phenotype
of lesional endothelial cells are believed not only to
be clinical and pathologic hallmarks of the disease,
but to play a central role in the pathogenesis of psor-
iatic plaques. Despite over 20 years of research by
leading angiogenesis experts and numerous studies,
many details regarding the cellular and molecular
basis for angiogenesis in psoriasis remain unknown.
In this review, 10 different sections are presented to
update recent progress in this active ®eld of investi-
gative skin biology. Highlights of this review include
the phenotypic characterization of endothelial cells
in acute and chronic psoriatic plaques, and a review
of a novel animal model of psoriasis using human
skin engrafted onto severe combined immunode®-
cient mice followed by injection of activated immu-
nocytes. This new experimental model represents a
reproducible and pharmacologically validated
method to trigger neovascularization and bona ®de
psoriatic plaque formation. In addition, the potential
contribution of epidermal keratinocytes and dermal
macrophages to the angiogenic tissue reaction is pre-
sented, and a series of questions are then posed that
can be answered using the severe combined immu-
node®cient mouse model of psoriasis. Finally, a
model is proposed integrating all available data into
a coherent multistep reaction schema that includes
active participation by multiple cell types including
natural killer T cells, keratinocytes, macrophages,
and microvascular endothelial cells. Key words:
endothelial cells/immunocytes/macrophages/T cells. Journal
of Investigative Dermatology Symposium Proceedings
5:67±73, 2000
P
soriasis is a chronic in¯ammatory disease characterized
by prominent epidermal proliferation (Wrone-Smith
and Nickoloff, 1996). Using a novel severe combined
immunode®cient (SCID) mouse:human skin chimeric
animal model, it has been established that activated
immunocytes are responsible for triggering the keratinocyte
hyperplasia producing a thick epidermis with altered differentiation
and scale production (Nickoloff et al, 1995; Boehncke et al, 1996;
Gilhar et al, 1997; Sugai et al, 1998; Yamamoto et al, 1998). In
addition to activated T cells and natural killer T cells being involved
in provoking rapid and substantial keratinocyte hyperplasia, the
engrafted skin samples also consistently display rather remarkable
and rapid new blood vessel formation (i.e., angiogenesis) following
injection of activated immunocytes (Boehncke et al, 1996;
Nickoloff et al, 1999). When engrafted prepsoriatic skin is injected
with saline, the dermal vascularization in the human dermis
contains only relatively inconspicuous blood vessels (Fig 1A), but
within 2 weeks of injection of activated immunocytes, the human
dermis contains numerous blood vessels representing an angiogenic
tissue reaction (Fig 1B). In dozens of injected grafts, psoriatic
plaques created in this model system are always accompanied by a
prominent angiogenic tissue reaction.
There are many changes in the blood vessels within a chronic,
well-established psoriatic plaque including: dilation of capillary
beds, increased capillary permeability, increased endothelial cell
proliferation, and tortuoisity of capillary loops with increase in
blood ¯ow through the skin (Braverman and Yen, 1977; Ryan,
1980; Braverman and Sibley, 1982; Klemp and Staberg, 1983;
Heng et al, 1991). The study of the vascular changes in psoriatic
plaques has been of interest to many leading scientists interested in
angiogenesis for several decades (Folkman, 1972, 1995). By using
the SCID mouse model, it is possible to determine the earliest
molecular and cellular changes in the epidermis and dermis
following injection of activated immunocytes that lead to the
characteristic angiogenic tissue response observed in psoriasis.
Previous investigators have observed that peripheral blood-
derived mononuclear cells from psoriatic patients, or serum from
psoriatic patients, could induce angiogenesis (Majewski et al, 1985,
1987); however, the exact cell-type (i.e., T cell subset), or the
molecules responsible for this angiogenic response, were not further
characterized. More recently, attempts have been made to de®ne
the cytokine network in psoriasis, and to identify angiogenic as well
as angiostatic cytokines that may contribute to the vascular changes
present in psoriatic plaques (Nickoloff, 1991). In this review, a
summary of the literature concerning the molecular and cellular
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basis for angiogenesis in psoriasis will be followed by a brief
discussion of currently unresolved questions, and a model for the
pathogenesis of psoriasis integrating all available data will conclude
the presentation.
CHARACTERIZATION OF PHENOTYPE OF
ACTIVATED ENDOTHELIAL CELLS IN CHRONIC
PSORIATIC PLAQUES
From a clinical and morphologic perspective, the prominent
vasculature in the super®cial plexus of a chronic psoriatic plaque
point to endothelial cell proliferation and activation (Wolfe, 1989).
To characterize the phenotype of the activated endothelial cell,
investigators have used immunohistochemical staining and com-
pared various antigens expressed by endothelial cells of normal skin
obtained from healthy individuals (NN skin), with clinically
symptomless skin removed from patients with psoriasis elsewhere
(PN skin), as well as chronic psoriatic plaques (PP skin). Because
the angiogenic pathway by which early endothelial cells sprout and
extend to form tubes and elongate capillary beds involves
interactions with extracellular matrix proteins, various integrins
have been examined (Ingber, 1992). Integrins are cell surface
molecules that play key roles in the angiogenic process because they
mediate cell±matrix interaction and trigger intracellular signaling
Figure 1.Angiogenic tissue reaction in en-
grafted prepsoriatic human skin transplanted
onto SCID mice. When orthotopically trans-
planted skin is injected with saline, no angiogen-
esis is present (A), but 2 weeks after injection of
activated immunocytes the human dermis contains
numerous small and large blood vessels re¯ecting a
local angiogenic tissue response that accompanies
the other clinical and microscopic changes charac-
teristic of a bona ®de plaque of psoriasis (B).
Figure 2.Differential expression of avb3 versus avb5 integrins in NN, PN, and chronic psoriatic plaques (PP skin), as well as acute psoriatic
lesions created using the SCID mouse model. Immunoperoxidase staining; Vectastain (anti-avb3 integrin MoAb; MoAb1976, and anti-aVb5 integrin
MoAb; MoAb1961; anti-ELAM-1; CD62E). 3-amino-4-ethylcarbazole as chromagen producing positive red reaction product. (A) avb3 expression is
absent in NN skin, but is focally present in PN skin and diffusely positive in endothelial cells in chronic PP skin. An acute psoriatic lesion created by injecting
activated autologous immunocytes into engrafted PN skin reveals endothelial cell positivity for avb3 integrin (panel labelled SCID). (B) avb5 expression is
focally present on upper dermal dendritic cells, and on basal keratinocytes and dermal dendritic cells in PN skin. In a chronic psoriatic plaque, while
perivascular and interstitial dendritic cells are avb5 positive, the endothelial cells are negative. An acute psoriatic lesion created on a SCID mouse (far right
panel) has strong and diffuse dendritic cell avb5 expression, but no endothelial cell positivity. Inset reveals ELAM-1 expression on microvascular endothelial
cells.
68 NICKOLOFF JID SYMPOSIUM PROCEEDINGS
producing endothelial cell activation and proliferation (Hynes,
1992).
In NN skin and PN skin there was low to absent expression of the
avb3 integrin (Brooks et al, 1994), but in psoriatic plaques there was
strong and diffuse endothelial cell expression of avb3 integrin
(Creamer et al, 1995). In our own series of six different skin
biopsies, we con®rmed these observations with respect to avb3
integrin expression (Fig 2). In contrast to this pattern for
avb3 integrin expression, there is actually a decrease in expression of
b4 integrin in PP skin compared with PN skin, and no change in b1
integrin expression between these different skin samples (Creamer
et al, 1995). Because cytokines can induce angiogenesis, Cheresh et al
have de®ned at least two different angiogenic pathways by differential
endothelial cell expression of avb3 versus avb5 integrins (Friedlander
et al, 1995). This group reported that avb3-dependent angiogenesis
was induced by basic ®broblast growth factor (bFGF) or tumor
necrosis factor alpha (TNF-a), whereas avb5-dependent angio-
genesis was triggered by either vascular endothelial growth factor
(VEGF), or transforming growth factor-a (TGF-a), or phorbol ester
(Friedlander et al, 1995). To examine the different expressions of
avb3 versus avb5, the same six NN, PN, and PP skin biopsies were
immunostained. Figure 2 reveals that while there was focal basal
keratinocytes and dermal dendritic cell expression of avb5 in NN and
PN skin, there was nodetectable endothelial cell positivity. Moreover
in all PP skin biopsies there was more extensive dermal dendritic cell
avb5 expression, but no endothelial cell positivity. The lack of
endothelial cell avb5 was rather surprising because the cytokine
network in psoriatic plaques includes the presence of VEGF and
TGF-a (inducers of avb5 in endothelial cells). We will return to this
topic later in the paper.
Before concluding this section, it should also be noted that there
are several other phenotypic characteristics that distinguish
endothelial cells in PP skin from endothelial cells in NN and PN
skin. Other surface antigens prominently expressed by endothelial
cells in PP skin include: endothelial cells adhesion molecule-1
(ELAM-1; also called E-selectin) (Petzelbauer et al, 1994),
intercellular adhesion molecule-1 (ICAM-1) (Groves et al, 1993),
vascular cell adhesion molecule-1 (VCAM-1) (Grif®ths et al, 1989),
and the MS-1 antigen (Goerdt et al, 1991). Thus, it is clear that the
endothelial cells express a wide variety of markers of activation that
distinguish them in the angiogenic tissue reaction characteristic of
chronic psoriatic plaques.
SWITCHING ON ANGIOGENESIS DURING WOUND
HEALING
Whereas the previous section focused on chronic psoriatic plaques,
in this section the focus will be on describing the dynamic
sequential events as recorded during cutaneous wound healing.
These types of experiments are relevant to the biology of psoriasis
as the ®nal psoriatic plaque may actually represent an abnormal
wound-healing response (Lingen and Nickoloff, 1999). There are
many different types of wound-healing models in which to study
the molecular and cellular basis of the regulation of angiogenesis,
but only three models will be discussed; one dealing with porcine
skin and the other two using human skin. In the porcine model, the
initiation of angiogenesis triggered by full-thickness wounding
Figure 3. Psoriatic plaque contains a rich admixture of macrophages and dendritic cells. The macrophage population includes a pan-macrophage
marker CD14, macrophages with classical activation markers (i.e., CD16, CD32) as well as alternatively activated macrophages (CD163, mannose receptor).
In addition, there are epidermal and dermal dendritic cells expressing CD1a, CD80, and CD83, indicating various degrees of maturation of these professional
antigen-presenting cells.
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revealed the transient functional involvement of the avb3 integrin
by endothelial cells, but not avb5 or b1 integrins (Clark et al,
1996). When NN skin was engrafted onto SCID mice, a
longitudinal dermo±epidermal excisional wound was created and
the subsequent wound healing and angiogenesis process was
investigated (Christo®dou-Solonidou et al, 1997). As early as 2 days
after wounding, there was upregulation of avb3, avb5, and avb6
integrins by the proliferating endothelial cells, but only inhibitors of
avb3 integrin blocked new vessel formation during human wound
healing (Christo®dou-Solonidou et al, 1997). To de®ne the
primary mediators of angiogenesis in acute wound repair, surgical
wound ¯uid was collected from surgical patients undergoing
mastectomy or neck dissection from postproductive days 1±7
(Nissen et al, 1998). It was determined that the initial angiogenic
stimulus was provided by bFGF-2, which was followed by a more
sustained pro-angiogenic stimulus elicited by VEGF (Nissen et al,
1998). The early appearance of bFGF-2 that peaked almost
immediately after surgery was presumably released from cells or
sequestered by extracellular matrix, and could account for the
subsequent upregulation of avb3 integrin expression as noted
earlier by the investigators.
PHENOTYPE OF DERMAL TISSUE REACTION DURING
GENESIS OF PSORIATIC LESIONS
Up until recently, it was dif®cult to reproducibly induce and study
the onset of psoriasis because no suitable animal model was
available; however, with the advent of transplantation technology
and availability of SCID mice, an animal model using entirely
human skin components was developed and validated (Nickoloff
et al, 1995). It is now possible to inject either engrafted PN or NN
skin and create psoriatic plaques that include a prominent
angiogenic tissue response (Boehncke et al, 1996; Nickoloff et al,
1999). This neovascularization of human dermis takes place within
2±4 weeks following intradermal injection of activated immuno-
cytes (Nickoloff et al, 1999). By using this experimental model
system we have begun to characterize the phenotype of the acutely
activated and proliferating human dermal microvascular endothelial
cells. Figure 2 reveals that acute lesion of psoriasis includes
endothelial cells that express avb3, but not avb5 integrins. In
addition, note the expression of ELAM-1 by the endothelial cells
(Fig 2, inset). Thus, as regards the differential expression of
integrins, the acutely generated angiogenic tissue response is similar
to chronic psoriatic plaques with respect to the phenotype of the
vascular endothelial cells.
Now that we can use this experimental approach in which
prominent angiogenesis is rapidly and predictably induced by the
injection of activated immunocytes including T cells and natural
killer T cells, it will now be possible to more fully explore the
molecular mechanisms governing this remarkable change in the
clinical and histologic appearance of the skin (Boehncke et al, 1996;
Nickoloff and Wrone-Smith, 1999; Nickoloff et al, 1999).
POTENTIAL DIRECT MEDIATORS PRODUCED BY
ACTIVATED T CELLS THAT CAN MODULATE
ANGIOGENESIS
Perhaps the simplest view of how the injection of activated
immunocyte triggers psoriasis is to consider a direct interaction by
which T cells themselves can serve as the source of pro-angiogenic
stimuli. This is a reasonable and straightforward possibility as it is
well documented that activated T cells can produce pro-angiogenic
responses by endothelial cells. Examples of such T cell-derived
factors include various cytokines (Lingen and Nickoloff, 1999), as
well as scatter factor (hepatocyte growth factor) (Naidu et al, 1994).
Scatter factor is a potent angiogenic factor that is present in psoriatic
plaques (Grant et al, 1993). Besides pro-angiogenic cytokines, it
should also be remembered that T cells in psoriatic plaques also
produce cytokines that have direct antiangiogenic effects such as
gamma interferon (IFN-g) and interferon inducible protein 10 (IP-
10) (Reaman and Tosato, 1995). IFN-g has pleiotropic effects
(Boehm et al, 1997), as it also is a potent inducer of nitric oxide that
can have profound effects on the microvasculature including
prominent vasodilation (Xie et al, 1993; Kolb-Bachofen et al, 1994).
Thus, it should be clear that there are both positive and negative
regulators of microvasculature growth, and that the overall balance
amongst these factors determines the ®nal net result with each tissue
site of interest (Folkman, 1995).
ACTIVATED T CELLS CAN INFLUENCE ENDOTHELIAL
CELLS INDIRECTLY VIA THE EPIDERMAL
KERATINOCYTE
Prior to the discovery of cytokines, epidermal keratinocytes were
viewed as rather immunologically inert cells, primarily relegated to
a brick and mortar function as regards the barrier function of skin.
When T cells were present in the skin, keratinocytes were
portrayed as simple passive targets not capable of either initiating or
perpetuating in¯ammatory or immune-mediated reactions (Barker
et al, 1991). It is now clear, however, that keratinocytes are
important coconspirators with T cells and dendritic cells, and can
even function as nonprofessional antigen presenting cells (Nickoloff
and Turka, 1993). The ability of keratinocytes to produce various
cytokines, chemotactic polypeptides, and adhesion molecules has
Figure 4.Model for understanding the cellular
and molecular basis for the angiogenic tissue
reaction in psoriasis highlighting the role of
activated immunocytes producing cytokines
that trigger neovascularization of the dermis.
The upper panels depict the microscopic and clin-
ical appearance of symptomless skin engrafted onto
a SCID mouse, and the subsequent psoriatic pla-
que that is created following injection of activated
immunocytes (inset includes prominent neovascu-
larization of dermis underlying newly created
psoriatic plaque). The lower panels represent a
model in which the intradermal injected activated
immunocytes (i.e., natural killer T cells) produce
cytokines such as IFN-g that are accompanied by
several keratinocyte-derived, macrophage-derived,
and dermal dendrocyte-derived pro-angiogenic
factors. The net result of this cytokine network is
activation and proliferation of aVb3 integrin posi-
tive endothelial cells.
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led to the recognition that they can in¯uence events in dermis
including the activation of endothelial cells (Grif®ths and
Nickoloff, 1991; Detmar et al, 1995; Reaman and Tosato, 1995).
In this section we will discuss the series of reciprocal interactions by
which activated T cells and natural killer T cells move from the
dermis into the epidermis and release cytokines that activate
keratinocytes, which in turn release additional cytokines that can
then activate dermal microvascular endothelial cells in psoriasis.
The two most important primary cytokines in psoriatic plaques
are IFN-g and TNF-a (Nickoloff, 1991). These cytokines can
in¯uence keratinocytes to produce a wide array of other cytokines
that have angiogenic activity. Examples of pro-angiogenic
regulators produced by cytokine activated keratinocytes include:
transforming growth factor-alpha (TGF-a) (Gottlieb et al, 1988;
Elder et al, 1989), VEGF (Detmar et al, 1994), IL-8 (Schroder and
Christophers, 1986; Nickoloff et al, 1991), scatter factor (Grant DS
et al, 1993), and TNF-a (Ettchad et al, 1994). In addition to these
pro-angiogenic cytokines, psoriatic keratinocytes underproduce the
angioinhibitory molecule thrombospondin (Nickoloff et al, 1994).
Given the mitogenic activity of several of these cytokines to also
promote further keratinocyte hyperplasia, which can contribute to
elongation of psoriatic capillaries (Bacharach-Buchies et al, 1994),
and the net pro-angiogenic pro®le of this cytokine network, it is
clear that keratinocytes activated by T cells can promote the
vascular proliferation that is a hallmark of the psoriatic plaque.
ACTIVATED T CELLS AND NATURAL KILLER T CELL
INTERACTION WITH MACROPHAGES THAT
TRIGGERS ANGIOGENESIS
One of the earliest cellular interactions to occur in the skin during
the onset of psoriatic lesions involves lymphocytes and macro-
phages (Schubert and Christophers, 1985). There are also important
reactions between T cells and dermal dendritic cells that contribute
to the release of cytokines that impact endothelial cells (Nestle et al,
1994). Numerous investigators have documented the presence of
various types of monocyte/macrophage and dendritic cells in and
around the blood vessels of psoriatic plaques (Paukkonen et al,
1992; Goerdt et al, 1993; Schopf et al, 1993; Sterry and Boehncke,
1993; Oord Van Den and Wolf-Peeters, 1994; Djemadji-Oudjel
et al, 1996). Rather than reviewing how the local immune reaction
is generated involving antigen presenting cells and T cells, in this
section a brief review of the importance of how T cells can impact
macrophages, followed by how these activated macrophages can
impact endothelial cells will be highlighted.
Up until recently, macrophages and dendritic cells were believed
to be of distinct origins with nonoverlapping phenotypes and
functions (Banchereau and Steinman, 1998); however, it is now
clear that monocytes can give rise to dendritic cells and that
dendritic cells can undergo phagocytosis (the term dendrophage
was introduced to signify this point) (Nickoloff and Nestle, 1995).
Currently, it is also possible to delineate at least two different
pathways for the activation of macrophages as well as dendritic cells
(Goerdt and Orfanos, 1999). These pathways have been identi®ed
as either involving classical activation versus alternative activation(s).
It has been suggested that acute in¯ammatory processes may be
perpetuated into chronic conditions because of these antigen
presenting cells (i.e., macrophage and dendritic cells) (Goerdt and
Orfanos, 1999). The classical activation pathway involves cytokines
such as IL-1, IL-6, IL-12, IFN-g, and TNF-a whereas the
alternative activation pathway involves the TH2 type cytokines IL-
4 and IL-10. The classical macrophage pathways mediates
immunologic reactions that produce in¯ammation, whereas the
alternative macrophage pathway is envisioned as a counter-
regulatory process predominantly manifesting itself with down-
regulation of in¯ammation, angiogenesis, and elimination of tissue
debris via phagocytosis as occurs during wound healing.
A classical activation-type macrophage has a distinctive im-
munophenotypic pro®le of cell surface markers including CD16,
CD32, and CD64; whereas the alternatively activated macrophage
does not express these markers, but does express CD163 and the
macrophage mannose receptor (MMR) (Goerdt and Orfanos,
1999). One previous report demonstrated the presence of
alternatively activated macrophages in psoriasis, but did not
examine the same biopsies for evidence of classical activated
macrophages or dendritic cells (Djemadji-Oudjel et al, 1996). To
determine if alternatively activated macrophages are the dominant
macrophage population in psoriasis, we examined a series of
psoriatic plaques with a broad panel of monoclonal antibodies.
Because alternatively activated macrophages have been linked to
angiogenic responses (Goerdt and Orfanos, 1999), we were
intrigued by the possible role for such cells in psoriasis.
As shown in Fig 3, a chronic psoriatic plaque contains a rich
admixture of dendritic cells and macrophage-appearing cells in the
upper dermis immunoreactive for the classical activation markers
CD16 and CD32. In addition, there are also numerous positively
stained mononuclear cells with alternative activation markers
CD163 and MMR. Thus it appears that both types of activated
cell phenotypes are present in psoriatic plaques. Once activated,
macrophages can induce prominent and rapid angiogenesis by
secreting various mediators including TNF-a, TGF-a, IGF-1,
PDGF-B, TGF-b, and scatter factor (Leibovich et al, 1987; Kodelja
et al, 1997). Further studies are indicated to determine their relative
importance and functional contribution to the in¯ammatory
process and angiogenic tissue reaction.
MODEL LINKING THE GENETIC AND CELLULAR
FACTORS RESPONSIBLE FOR TRIGGERING THE
ANGIOGENIC TISSUE REACTION IN PSORIASIS
A line of inquiry that is currently being followed includes the
possibility that when one of our natural killer T cell lines is injected
into the dermis, because these natural killer T cells can produce both
IFN-g (classical activation pathways) as well as IL-4 and IL-13
(alternative activating pathway), neither opposing pathways can
become dominantly established within the ®rst 2 weeks (Nickoloff
et al 1999). We postulate this potentially unbalanced, and hence
dysfunctional interaction, ultimately results in a chronic in¯ammatory
reaction with neovascularization that persists for a long periodof time.
Our current working model includes several sequential cellular and
molecular events including the following (Fig 4). First, natural killer
T cells in®ltrate the dermis and, upon contact with relevant CD1d
bearing target cells such as epidermal keratinocytes, become activated
via their natural killer receptors such as CD161 (Bonish et al, 2000).
Second, these natural killer T cells begin producing a mixture of
cytokines including IFN-g and IL-13 (Nickoloff et al, 2000). Third,
the avascular epidermal-based keratinocytes also become activated to
release several pro-angiogenic cytokines that in¯uence the under-
lying vessels in a paracrine fashion. Fourth, the local production of
IFN-g and IL-13 activate tissue monocytes/macrophages/dendritic
cells and drive both classical as well as alternative activation pathways.
Finally, the tissue ``dendrophage'' release a variety of cytokines and
angiogenic molecules that provoke a local angiogenic tissue reaction.
The proliferating endothelial cells are characterized by a distinctive
phenotype including avb3 integrin expression as well as various
adhesion molecules including ELAM-1, VCAM-1, and ICAM-1.
Thus, the initial in¯ux of pathogenic immunocytes triggers a chain
reaction of cellular and molecular events involving both epidermal
keratinocytes as well as angiocentric and interstitial dermal macro-
phages and dendritic cells. It should be noted that the experimental
evidence for this new concept in which natural killer T cells can
trigger angiogenesis is still preliminary, and will require additional
study for comparison with more conventional T cell subsets.
REMAINING QUESTIONS THAT CAN BE ADDRESSED
USING THE SCID MOUSE ANIMAL MODEL OF
PSORIASIS
Perhaps the most important currently unsolved issues as regards
angiogenesis and psoriasis is whether the neovascularization is
required for the creation and/or maintenance of the plaque. Using
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the SCID mouse:human skin chimeric model it is now possible to
address this question by preinjecting the engrafted skin with
blocking antibodies against the most important integrins such as
avb3, followed by intradermal inoculation of activated immuno-
cytes. Alternatively, it is possible to add neutralizing antibody
against VEGF to determine the relative importance of angiogenesis
to psoriasis mediated by VEGF. If the angiogenic tissue response
can be inhibited, it will be interesting to observe the degree (if any)
of epidermal hyperplasia in such a setting. Similarly by injecting
engrafted psoriatic plaques with inhibitory antibodies against avb3
integrin or VEGF it could be determined whether the angiogenesis
could be reversed; and if it could, whether it would have any effect
on the extent of keratinocyte hyperplasia in the overlying
epidermis. The reagents available that antagonize or disrupt
angiogenic blood vessels do so by inducing apoptosis of the
endothelial cells (Brooks et al, 1994). An alternative approach to
using monoclonal antibodies would be to use cytokines such as IL-
12 and IL-18 to attack the hyperplastic endothelial cells, and then
observe the net effect on the psoriatic tissue (Coughlin et al, 1998).
Thus, by taking this approach, investigators will ®nally be able to
determine if the angiogenic response in the dermis is of primary or
secondary importance to the genesis and propagation of psoriatic
plaques.
Recent discoveries related to the positive and negative regulation
of blood vessel growth have propelled the ®eld of angiogenesis to
the forefront of biomedical research. While it is clear that the
majority of investigators are seeking to apply this new knowledge
to cancer therapy and to understanding tumorigenesis, it is likely
that these advances will impact our perspectives towards other
disease processes such as psoriasis, rheumatoid arthritis, and many
more medical conditions (Folkman, 1995). Even though a number
of exciting naturally occurring and synthetic negative regulators
have been discovered such as angiostatin, it will be important to
identify their target receptor(s) that are responsible for mediating
the antiangiogenic tissue response. While many cellular and
molecular mediators of angiogenesis in psoriasis have been
elucidated, many questions remain as discussed in the previous
section. Nonetheless, with the development of the SCID mouse
animal model as a validated and useful experimental tool, as well as
the rapid advances made by investigators studying other disease
processes (Eliceiri and Cheresh, 1999), it is likely that progress in
understanding and treating psoriasis by attacking the vasculature
will be part of our therapeutic strategy in the not so distant future.
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